Table 3.
Estimated Survival Rates According to Recurrence Score and Assigned Treatment among Women 50 Years of Age or Younger in the Intention-to-Treat Population.*
| End Point and Treatment Group | Rate at 5 Yr | Rate at 9 Yr |
|---|---|---|
| percent | ||
| Invasive disease-free survival† | ||
| Score of ≤ 1O. endocrine therapy | 95.1±1.1 | 87.4±2.0 |
| Score of 11–15. endocrine therapy | 95.1±1.1 | 85.7±2.2 |
| Score of 11–15. chemoendocrine therapy | 94.3±1.3 | 89.2±1.9 |
| Score of 16–20. endocrine therapy | 92.0±1.3 | 80.6±2.5 |
| Score of 16–20. chemoendocrine therapy | 94.7±1.1 | 89.6±1.7 |
| Score of 21–25. endocrine therapy | 86.3±2.3 | 79.2±3.3 |
| Score of 21–25. chemoendocrine therapy | 92.1±1.8 | 85.5±3.0 |
| Score of ≥ 26. chemoendocrine therapy | 86.4±1.9 | 80.3±2.9 |
| Freedom from recurrence of breast cancer at a distant site | ||
| Score of ≤ 1O. endocrine therapy | 99.7±0.3 | 98.5±0.8 |
| Score of 11–15. endocrine therapy | 98.8±0.6 | 97.2±1.0 |
| Score of 11–15. chemoendocrine therapy | 98.5±0.7 | 98.0±0.8 |
| Score of 16–20. endocrine therapy | 98.1±0.7 | 93.6±1.4 |
| Score of 16–20. chemoendocrine therapy | 98.9±0.5 | 95.2±1.3 |
| Score of 21–25. endocrine therapy | 93.2±1.7 | 86 9±2.9 |
| Score of 21–25. chemoendocrine therapy | 96.4±1.2 | 93.4±2.3 |
| Score of ≥ 26. chemoendocrine therapy | 91.1±1.6 | 88 7±2.1 |
| Freedom from recurrence of breast cancer at a distant or local-regional site | ||
| Score of≤1O. endocrine therapy | 98.4±0.6 | 95.4±1.3 |
| Score of 11–15. endocrine therapy | 97.5±0.8 | 93.3±1.6 |
| Score of 11–15. chemoendocrine therapy | 97.2±0.9 | 94.4±1.5 |
| Score of 16–20. endocrine therapy | 95.7±1.0 | 89.6±1.9 |
| Score of 16–20. chemoendocrine therapy | 97.2±0.8 | 93.0±1.5 |
| Score of 21–25. endocrine therapy | 89.8±2.0 | 82.0±3.2 |
| Score of 21–25. chemoendocrine therapy | 94.2±1.6 | 90.7±2.5 |
| Score of ≥ 26. chemoendocrine therapy | 88.6±1.8 | 86.1±2.2 |
| Overall survival | ||
| Score of≤1O. endocrine therapy | 100.0 | 98.6±0.9 |
| Score of 11–15. endocrine therapy | 99.3±0.4 | 96.8±1.0 |
| Score of 11–15. chemoendocrine therapy | 98.9±0.6 | 97.5±0.9 |
| Score of 16–20. endocrine therapy | 98.6±0.6 | 95.8±1.2 |
| Score of 16–20. chemoendocrine therapy | 99.8±0.2 | 96.1±1.2 |
| Score of 21–25. endocrine therapy | 98.2±0.9 | 92.7±2.0 |
| Score of 21–25. chemoendocrine therapy | 98.3±0.8 | 93.9±1.9 |
| Score of ≥ 26. chemoendocrine therapy | 95.6±1.1 | 92.4±1.9 |
*
Plus–minus values are Kaplan–Meier estimates ±SE.
†
Invasive disease–free survival was defined as freedom from invasive disease recurrence, second primary cancer, or death.